WHO mass-testing three potential COVID-19 treatments
Clinicians work on intubating a COVID-19 patient in the Intensive Care Unit at Lake Charles Memorial Hospital on August 10 in Louisiana.
The World Health Organization on Wednesday announced major international trials of three drugs to find out whether they improve the condition of hospitalized COVID-19 patients.
Artesunate, imatinib and infliximab will be tested on thousands of volunteer patients in more than 600 hospitals in 52 countries and regions.
"Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need," said WHO director-general Tedros Adhanom Ghebreyesus.
Artesunate is a treatment for severe malaria; imatinib a drug used for certain cancers and infliximab a treatment for immune system disorders such as Crohn's and rheumatoid arthritis.
The coordinated research across dozens of countries allows the trial to assess multiple treatments using a single protocol, thereby generating robust estimates on the effect a drug may have on mortality, including moderate effects, said the WHO.
The drugs were chosen by an independent expert panel for their potential in reducing the risk of death in hospitalized COVID-19 patients.
They were donated for the trial by their manufacturers and are already being shipped out to the hospitals involved.
Previous trial's dead end
The testing of artesunate, imatinib and infliximab on COVID-19 patients is the second stage of the WHO's Solidarity hunt for effective treatments against the killer disease.
Previously, four drugs were evaluated by the Solidarity trial, involving almost 13,000 patients in 500 hospitals across 30 countries.
The provisional results issued in October showed that remdesivir, hydroxychloroquine, lopinavir and interferon had little or no effect on hospitalized patients with COVID-19.
The final results are due out next month.
"We already have many tools to prevent, test for and treat COVID-19, including oxygen, dexamethasone and IL-6 blockers. But we need more, for patients at all ends of the clinical spectrum, from mild to severe disease," Tedros told a news conference.
The WHO COVID-19 Therapeutics Advisery Group recommended evaluating the anti-inflammatory properties of artesunate, which has been extensively used in the treatment of malaria and other parasitic diseases for more than 30 years, and is regarded as being very safe.
A randomized clinical trial in the Netherlands reported that imatinib, a small molecule tyrosine kinase inhibitor, might confer clinical benefit in hospitalized COVID-19 patients.
Meanwhile infliximab has shown favorable efficacy and safety in restricting broad spectrum inflammation, including in the elderly populations who are the most clinically vulnerable to COVID-19.
